Lemaitre Vasculr Stock Price, News & Analysis

LeMaitre Vascular (Nasdaq: LMAT) reported Q3 2025 results and raised guidance on Nov. 6, 2025. Q3 sales were $61.0mm (+11% overall, +12% organic). GAAP operating income was $20.3mm (+54%) and diluted EPS was $0.75 (+54%); non-GAAP adjusted operating income was $16.9mm (+29%) and adjusted EPS was $0.62 (+27%). Adjusted gross margin was 70.8% (up 300 bps). Cash rose by $23.6mm sequentially to $343.1mm. Growth drivers: grafts +23%, shunts +18%, Artegraft +33% (international launch). Regional sales: EMEA +18%, Americas +10%, APAC +4%. The board declared a quarterly dividend of $0.20/share payable Dec. 4, 2025, and authorized a $75.0mm share repurchase program through Feb. 17, 2026. Guidance: FY 2025 mid‑sales of $248mm (+13%) and adjusted full‑year operating income mid of $63.7mm.

LeMaitre Vascular (NASDAQ:LMAT) will release its third quarter 2025 financial results on Thursday, November 6, 2025 after the market close. A conference call to discuss results, business highlights, and outlook is scheduled the same day at 5:00 PM EST. Investors can register for live dial‑in access and a PIN or listen via a live audio webcast and replay at the company's investor site.

LeMaitre Vascular (Nasdaq:LMAT) announced its participation in four upcoming investor conferences in September 2025. CFO Dorian LeBlanc will represent the company at the Wells Fargo Healthcare Conference (Sept 3), Cantor Global Healthcare Conference (Sept 4), Morgan Stanley Global Healthcare Conference (Sept 9), and the virtual Barrington Research Fall Investment Conference (Sept 16).

LeMaitre Vascular (Nasdaq: LMAT) reported strong Q2 2025 financial results with sales reaching $64.2 million, up 15% year-over-year. The company achieved notable performance metrics including a gross margin of 70.0% (up 110 bps), operating income of $16.1 million (up 12%), and earnings per diluted share of $0.60 (up 16%).

Growth was driven by strong performance in catheters (+27%) and grafts (+19%), with robust regional sales increases in EMEA (23%), Americas (12%), and APAC (12%). The company raised its 2025 guidance, announced a $0.20 quarterly dividend, and maintains an active $75.0 million share repurchase program through February 2026.

LeMaitre Vascular (Nasdaq:LMAT) has scheduled its second quarter 2025 financial results announcement for Tuesday, August 5, 2025, after market close. The company will host a conference call at 5:00 PM EDT on the same day to discuss quarterly results, business highlights, and future outlook.

Investors can access the live call by registering online, after which they will receive dial-in information and a PIN. Additionally, an audio webcast will be available both live and for replay through the company's investor relations website at ir.lemaitre.com.

LeMaitre Vascular (NASDAQ:LMAT) announced that its President, David Roberts, will present at the Bank of America Securities 2025 Healthcare Conference. The presentation is scheduled for Tuesday, May 13, 2024, at 5:00 PM PDT and will take place at the Encore at the Wynn Hotel in Las Vegas, NV.

LeMaitre Vascular reported strong Q1 2025 financial results with sales reaching $59.9 million, up 12% (13% organic). The company achieved a gross margin of 69.2% and operating income of $12.6 million, up 6%. Earnings per share increased 10% to $0.48. Growth was driven by grafts (+17%) and carotid shunts (+14%), with EMEA sales up 18%. The company announced a $0.20 quarterly dividend and increased its 2025 guidance, now expecting sales of $245 million (+12%) and EPS of $2.16 (+12%). Notably, Artegraft received MDR CE Mark approval, enabling European market expansion. The company maintains a strong cash position of $302.5 million and has authorized a $75 million share repurchase program.

LeMaitre Vascular (NASDAQ:LMAT) has scheduled its first quarter 2025 financial results announcement for Thursday, May 1, 2025, after market close. The company will host a conference call at 5:00 PM EDT on the same day to discuss quarterly results, business highlights, and future outlook. Interested participants can access the live call by registering online, after which they will receive dial-in information and a PIN. Additionally, an audio webcast will be available both live and for replay through the company's investor relations website.

LeMaitre Vascular (Nasdaq: LMAT) has announced its upcoming participation in the 24th Annual Needham Virtual Healthcare Conference. The company's management team is scheduled to deliver their presentation on Tuesday, April 8, 2025, at 3:45 PM EDT. This virtual event represents an opportunity for investors and healthcare industry stakeholders to gain insights into LeMaitre's operations and strategic initiatives.